ERM has acted for Gilde Healthcare, a Dutch-based healthcare investor that has a portfolio of investments across Europe, on their $20 million investment in Nyxoah S.A., a medical device company focused on developing a neuro-stimulation based therapy for patients suffering from Obstructive Sleep Apnea (OSA).
The proceeds will be used to finance Nyxoah’s go-to-market strategy, including the BLAST OSA international study, CE Mark approval and the US FDA approval process.
Gilde Healthcare led the financing with participation from Belgium based investors SRIW and Novallia.
Simon Marks, co-head of our high-tech and start-ups practice, led the team.
For media coverage of the investment, please click here.
High-Tech and Start-ups practice
Epstein Rosenblum Maoz (ERM)’s high-tech and start-ups practice regularly provides legal advice to leading Israeli and international clients from pre-incorporation through to exit, as well as on the most complex transactions carried out in Israel and abroad.
For more information on the investment or our high-tech and start-ups practice, please contact Simon Marks, or another member of our team.